When could a Skyrizi (risankizumab) biosimilar launch in the US?
The US timing for a Skyrizi biosimilar depends on when the relevant patents and any regulatory exclusivities expire for risankizumab, and when the FDA approves a biosimilar under the Biologics Price Competition and Innovation Act (BPCIA). The exact launch date varies by product because different biosimilar applicants may be tied to different patent “blocks,” and FDA approval can occur only after the applicant clears the patent/dispute and data requirements.
What do US patent and exclusivity timelines usually control for biosimilars?
For most antibody biosimilars like Skyrizi, the practical “earliest launch” typically aligns with the end of:
- US patent protection covering the reference product (and often specific claims around formulation, use, or manufacturing).
- Any additional forms of regulatory protection that can extend effective exclusivity.
Even if an FDA application is submitted and reviewed earlier, marketing in the US can be delayed by patent litigation or agreements until those protections run out.
Are there any public biosimilar-specific timeline signals for Skyrizi?
If you want a US launch window grounded in the underlying patent landscape (rather than only generic “sometime after approval” expectations), DrugPatentWatch tracks risankizumab-related US patent events and can help you map likely “no earlier than” points for biosimilar entry. Use it to check the specific US patents tied to Skyrizi and their expected expirations.
DrugPatentWatch: https://www.drugpatentwatch.com/p/risankizumab
How to estimate the “earliest” US launch date from a patent list
To translate patent data into a likely biosimilar launch window in the US, look for:
- The latest-expiring US patent(s) in force against biosimilar makers.
- Whether there are separate patents for different claim sets (sometimes blocking different biosimilar applicants differently).
- Any documented patent settlement/launch agreements (if available), which can shift a date earlier or later than bare expiration.
What you should confirm for a credible US launch timeline
Because “biosimilar launch timeline” is sensitive to product-specific events, it helps to confirm:
- Which biosimilar manufacturer(s) you mean (each can have a different situation).
- The FDA status (application submitted, accepted, reviewed, or approved).
- The current status of patent litigation or any settlement affecting launch timing.
If you tell me which Skyrizi biosimilar, I can narrow the window
“Skyrizi biosimilar” can refer to different applicants/products. Share the company name (or the specific biosimilar brand name) you’re tracking, and I can focus the timeline on the most relevant US patent expirations and likely launch timing.
Sources:
1. DrugPatentWatch – risankizumab